Abstract: Embodiments of the disclosure encompass methods and compositions related to modulating the Hippo pathway to inhibit fibrosis and/or inflammation in a tissue and/or organ of an individual in need thereof. In specific embodiments, the disclosure concerns modulation of LATS1, LATS2, or both, such as providing to the individual an effective amount of one or more agents that increase the levels of LATS1, LATS2, or both in the individual. In specific cases, cardiac fibrosis is treated with effective levels of vector(s) comprising LATS1, LATS2, or both.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal. In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.

Abstract: Various implementations include portable speakers with detachable wireless transmitters. In some particular aspects, a portable speaker includes an enclosure housing: at least one electro-acoustic transducer for providing an audio output, a processor coupled with the at least one transducer; an audio input module coupled with the processor for receiving audio input signals; and an input channel for receiving a hard-wired audio input connection at the enclosure; at least one wireless transmitter detachably housed in the enclosure and in communication with a corresponding wireless input channel for receiving audio input from a source device.

Abstract: Various implementations include portable speakers with detachable wireless transmitters. In some particular aspects, a portable speaker includes an enclosure housing: at least one electro-acoustic transducer for providing an audio output, a processor coupled with the at least one transducer; an audio input module coupled with the processor for receiving audio input signals; and an input channel for receiving a hard-wired audio input connection at the enclosure; at least one wireless transmitter detachably housed in the enclosure and in communication with a corresponding wireless input channel for receiving audio input from a source device.

Abstract: Embodiments of the disclosure include methods for generating skeletal muscle by targeting the Hippo pathway. In particular embodiments, an individual with a need for skeletal muscle generation is provided an effective amount of a shRNA molecule that targets the SAV1 gene. Particular shRNA sequences are disclosed.

Abstract: Various implementations include portable speakers with dynamic display characteristics. In some particular aspects, a portable speaker includes an enclosure housing: at least one electro-acoustic transducer for providing an audio output; a processor coupled with the at least one transducer; an audio input module coupled with the processor for receiving audio input signals; and a battery configured to power the at least one transducer, the processor, and the audio input module; an input channel for receiving a hard-wired audio input connection; at least one wireless input channel for receiving an audio input from a source device via a wireless connection; and a display on the enclosure coupled with the processor, wherein the processor adjusts an orientation of the display between a first orientation and a second orientation in response to detecting a change in orientation of the portable speaker.

Abstract: Various implementations include portable speakers with detachable wireless transmitters. In some particular aspects, a portable speaker includes an enclosure housing: at least one electro-acoustic transducer for providing an audio output, a processor coupled with the at least one transducer; an audio input module coupled with the processor for receiving audio input signals; and an input channel for receiving a hard-wired audio input connection at the enclosure; at least one wireless transmitter detachably housed in the enclosure and in communication with a corresponding wireless input channel for receiving audio input from a source device.

Abstract: Various implementations include portable speakers with dynamic display characteristics. In some particular aspects, a portable speaker includes an enclosure housing: at least one electro-acoustic transducer for providing an audio output; a processor coupled with the at least one transducer; an audio input module coupled with the processor for receiving audio input signals; and a battery configured to power the at least one transducer, the processor, and the audio input module; an input channel for receiving a hard-wired audio input connection; at least one wireless input channel for receiving an audio input from a source device via a wireless connection; and a display on the enclosure coupled with the processor, wherein the processor adjusts an orientation of the display between a first orientation and a second orientation in response to detecting a change in orientation of the portable speaker.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure encompass methods and compositions related to modulating the Hippo pathway to inhibit fibrosis and/or inflammation in a tissue and/or organ of an individual in need thereof. In specific embodiments, the disclosure concerns modulation of LATS1, LATS2, or both, such as providing to the individual an effective amount of one or more agents that increase the levels of LATS1, LATS2, or both in the individual. In specific cases, cardiac fibrosis is treated with effective levels of vector(s) comprising LATS1, LATS2, or both.

Abstract: Embodiments of the disclosure include methods and compositions related to the proliferation of cardiomyocytes. In particular embodiments, the proliferation of cardiomyocytes is facilitated upon exposure of the cardiomyocytes to agents that affect the sequestering of Yap by dystrophin glycoprotein complex, such agents including those that inhibit DAG1, Yap, or the interaction thereof.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.